

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED
AUG 29 2000
File Information Unit

In re Application of

Dale J. Kempt

Application Number

07/998114

Filed

3.29.1995

Group Art Unit

Examiner

Paper No. #13

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

___ (A) referred to in United States Patent Number 5,674,882, column ___.

___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.

___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Caroleen Freeman

Signature

8-29-2000

Date

Typed or printed name

FOR PTO USE ONLY

Approved by: [Signature]

(Initials)

Unit: File Information

United States Patent [19]

Kempf et al.

[11] Patent Number: 5,674,882

[45] Date of Patent: Oct. 7, 1997

[54] RETROVIRAL PROTEASE INHIBITING COMPOUNDS

[75] Inventors: Dale J. Kempf, Libertyville; Daniel W. Norbeck, Crystal Lake; Hing Leung Sham; Chen Zhao, both of Gurnee, all of Ill.

[73] Assignee: Abbott Laboratories, Abbott Park, Ill.

[21] Appl. No.: 413,136

[22] Filed: Mar. 29, 1995

Related U.S. Application Data

[60] Division of Ser. No. 158,587, Dec. 2, 1993, abandoned, which is a continuation-in-part of Ser. No. 998,114, Dec. 29, 1992, abandoned, which is a continuation-in-part of Ser. No. 777,626, Oct. 23, 1991, which is a continuation-in-part of Ser. No. 746,020, Aug. 15, 1991, abandoned, which is a continuation-in-part of Ser. No. 616,170, Nov. 20, 1990, abandoned, which is a continuation-in-part of Ser. No. 518,730, May 9, 1990, Pat. No. 5,142,056, which is a continuation-in-part of Ser. No. 456,124, Dec. 22, 1989, abandoned, which is a continuation-in-part of Ser. No. 405,604, Sep. 8, 1989, abandoned, which is a continuation-in-part of Ser. No. 355,945, May 23, 1989, abandoned.

[51] Int. Cl.⁶ A61K 31/41

[52] U.S. Cl. 514/365; 514/374

[58] Field of Search 514/365, 374

[56] References Cited

U.S. PATENT DOCUMENTS


4,172,094 10/1979 Dybas et al. 544/396
 4,618,619 10/1986 Regel et al. 514/383
 4,644,055 2/1987 Kettner et al. 530/330
 4,652,552 3/1987 Kettner et al. 514/18
 5,142,056 8/1992 Kempf et al. 546/265
 5,354,866 10/1994 Kempf et al. 546/265

Primary Examiner—Russell Travers

Attorney, Agent, or Firm—Steven R. Crowley

[57] ABSTRACT

A retroviral protease inhibiting compound of the formula:



is disclosed.

3 Claims, No Drawings